卡铂联合或不联合维利帕尼加入标准新辅助化疗治疗三阴性乳腺癌的长期疗效与安全性:BrighTNess随机III期试验4年随访数据
BrighTNess III期试验4.5年随访显示,在每周紫杉醇基础上加用卡铂(联合或不联合维利帕尼)较单用紫杉醇改善无事件生存(EFS),卡铂+维利帕尼+紫杉醇 vs 紫杉醇 HR 0.63(95%CI 0.43-0.92,P=0.02),但卡铂+维利帕尼+紫杉醇 vs 卡铂+紫杉醇 HR 1.12(95%CI 0.72-1.72,P=0.62);总生存(OS)组间无显著差异,第二恶性肿瘤风险未增加。
要点
- 卡铂+维利帕尼+紫杉醇 vs 紫杉醇 EFS HR 0.63(95%CI 0.43-0.92,P=0.02)
- 卡铂+维利帕尼+紫杉醇 vs 卡铂+紫杉醇 EFS HR 1.12(95%CI 0.72-1.72,P=0.62)
- 事后分析卡铂+紫杉醇 vs 紫杉醇 EFS HR 0.57(95%CI 0.36-0.91,P=0.02)
核心结论
- 在每周紫杉醇基础上加用卡铂带来的病理完全缓解(pCR)改善与长期EFS获益相关,安全性可控,且不增加第二恶性肿瘤风险,而加用维利帕尼未影响EFS。
- 这些发现支持在早期三阴性乳腺癌(TNBC)新辅助化疗中,将卡铂加入每周紫杉醇后序贯多柔比星和环磷酰胺的方案。
研究设计与样本
- III期BrighTNess随机试验,纳入未经治疗的II-III期TNBC女性,按2:1:1随机分配至三组。
- A组:紫杉醇(每周12次)联合卡铂(每3周一次,共4周期)联合维利帕尼(每日两次);B组:紫杉醇联合卡铂联合维利帕尼安慰剂;C组:紫杉醇联合卡铂安慰剂联合维利帕尼安慰剂。
- 所有患者随后接受多柔比星和环磷酰胺每2-3周一次,共4周期;主要终点为pCR,次要终点包括EFS、OS和安全性。
- 因卡铂+维利帕尼+紫杉醇 vs 卡铂+紫杉醇的pCR共同主要终点未达到,次要分析为描述性。
- 共634例患者:A组316例,B组160例,C组158例。
主要发现
- 中位随访4.5年,A组 vs C组 EFS HR 0.63(95%CI 0.43-0.92,P=0.02)。
- A组 vs B组 EFS HR 1.12(95%CI 0.72-1.72,P=0.62)。
- 事后分析中,B组 vs C组 EFS HR 0.57(95%CI 0.36-0.91,P=0.02)。
- OS在各治疗组间无显著差异,骨髓增生异常综合征、急性髓系白血病或其他第二恶性肿瘤的发生率亦无显著差异。
临床怎么用
- 作者认为,这些发现支持在早期TNBC的新辅助化疗中,将卡铂加入每周紫杉醇后序贯多柔比星和环磷酰胺的方案。
局限性
- 因卡铂+维利帕尼+紫杉醇 vs 卡铂+紫杉醇的pCR共同主要终点未达到,次要分析为描述性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary analyses of the phase III BrighTNess trial showed addition of carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved pathological complete response (pCR) rates with manageable acute toxicity in patients with triple-negative breast cancer (TNBC). Here, we report 4.5-year follow-up data from the trial. PATIENTS AND METHODS: Women with untreated stage II-III TNBC were randomized (2 : 1 : 1) to paclitaxel (weekly for 12 doses) plus: (i) carboplatin (every 3 weeks for four cycles) plus veliparib (twice daily); (ii) carboplatin plus veliparib placebo; or (iii) carboplatin placebo plus veliparib placebo. All patients then received doxorubicin and cyclophosphamide every 2-3 weeks for four cycles. The primary endpoint was pCR. Secondary endpoints included event-free survival (EFS), overall survival (OS), and safety. Since the co-primary endpoint of increased pCR with carboplatin plus veliparib with paclitaxel versus carboplatin with paclitaxel was not met, secondary analyses are descriptive. RESULTS: Of 634 patients, 316 were randomized to carboplatin plus veliparib with paclitaxel, 160 to carboplatin with paclitaxel, and 158 to paclitaxel. With median follow-up of 4.5 years, the hazard ratio for EFS for carboplatin plus veliparib with paclitaxel versus paclitaxel was 0.63 [95% confidence interval (CI) 0.43-0.92, P = 0.02], but 1.12 (95% CI 0.72-1.72, P = 0.62) for carboplatin plus veliparib with paclitaxel versus carboplatin with paclitaxel. In post hoc analysis, the hazard ratio for EFS was 0.57 (95% CI 0.36-0.91, P = 0.02) for carboplatin with paclitaxel versus paclitaxel. OS did not differ significantly between treatment arms, nor did rates of myelodysplastic syndromes, acute myeloid leukemia, or other secondary malignancies. CONCLUSIONS: Improvement in pCR with the addition of carboplatin was associated with long-term EFS benefit with a manageable safety profile, and without increasing the risk of second malignancies, whereas adding veliparib did not impact EFS. These findings support the addition of carboplatin to weekly paclitaxel followed by doxorubicin and cyclophosphamide neoadjuvant chemotherapy for early-stage TNBC.
引用
- Geyer CE, Sikov WM, Huober J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol. 2022. PMID: 35093516. doi:10.1016/j.annonc.2022.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。